Browsing Tag
Melanoma
20 posts
Five-year data boosts Moderna and Merck’s neoantigen vaccine strategy in adjuvant melanoma
Moderna and Merck reveal 5-year data showing 49% reduction in melanoma recurrence with their mRNA-4157 and KEYTRUDA combo. Read more on what’s next.
Senhwa Biosciences strikes pivotal supply deal with BeOne Medicines for cold tumor breakthrough
Senhwa Biosciences and BeOne Medicines announce a global clinical trial to tackle cold tumors. Find out how this deal could change cancer immunotherapy.
Investors eye PHIO as Phio Pharmaceuticals reports full Phase 1b enrollment and strong preliminary PH-762 results
Find out how Phio Pharmaceuticals’ PH-762 trial progress and early response signals could reshape RNA-based cancer therapies.
Evaxion reports promising immune-biomarker results for AI-designed EVX-01 vaccine with KEYTRUDA
Discover how Evaxion’s AI-powered EVX-01 vaccine drives potent T-cell responses and strengthens its melanoma phase 2 program with KEYTRUDA.
How Bio-Techne and Nucleai’s AI spatial biology breakthrough could redefine melanoma biomarker discovery
Discover how Bio-Techne and Nucleai’s AI-powered spatial biology workflow is advancing predictive biomarker discovery in melanoma and transforming immunotherapy research.
RNAZ stock surges as TransCode Therapeutics buys Polynoma and wins $25m CK Life Sciences funding for metastatic cancer pipeline
Find out how TransCode Therapeutics’ $25M CK Life Sciences funding and Polynoma buyout could redefine RNAZ’s role in cancer immunotherapy.
What is gold nanorod therapy and how does Sona Nanotech plan to use it to treat late-stage melanoma patients?
Sona Nanotech’s gold nanorod cancer therapy is heading to human trials. Learn how its CTAB-free Targeted Hyperthermia Therapy works and what’s next for melanoma care.
Sun Pharmaceutical faces regulatory pause as EMA application for melanoma drug withdrawn
Sun Pharmaceutical’s EU partner Philogen has withdrawn its EMA application for Nidlegy, delaying regulatory progress in melanoma care. Read what’s next.
Innovent’s IBI363 gains NMPA breakthrough therapy designation, boosting regulatory momentum
Innovent’s IBI363 secures NMPA breakthrough therapy designation for melanoma. Discover its clinical potential, investment outlook, and global impact.
Bristol Myers Squibb’s Opdualag fails to meet primary endpoint in Phase 3 trial
Bristol Myers Squibb has announced that its Phase 3 RELATIVITY-098 clinical trial, designed to evaluate Opdualag (nivolumab and…